PATH | VRL
Menu

The Case for Investment in Enterotoxigenic Escherichia coli Vaccines

This market assessment aims to increase the awareness of biotechnology and pharmaceutical companies worldwide about the opportunities and potential markets that exist for low-cost and effective vaccines against enterotoxigenic Escherichia coli (ETEC). In addition, it provides donors and commercial investors with a better understanding of the potential risks, rewards, and gaps in knowledge relative to these opportunities as they consider their own investment strategies. The resulting analysis demonstrates that ETEC vaccines may represent a moderate opportunity for industry investment with an estimated annual revenue potential of more than US$600 million ten years after global launch.

Author: PATH; BIO Ventures for Global Health

Published: 2011

» Download file - report summary (English)

251 KB PDF

» Download file - full report (English)

5,789 KB PDF

Resource types: Report, PATH resource

Diseases/vaccines: Shigellosis and enterotoxigenic Escherichia coli (ETEC)

Topics: Disease burden and surveillance, Disease/vaccine specific information

Regions: Global